EMMYON - Key Persons

Christopher M. Adams - CEO, Founder, President

Job Titles:
  • CEO
  • Founder
  • Member of the Management Team
  • President
Chris Adams has served as President and CEO of Emmyon since 2012. He is an endocrinologist and clinician investigator in the Division of Endocrinology, Metabolism and Nutrition at Mayo Clinic. His research focuses on mechanisms and treatment of muscle atrophy and diabetes. His clinical practice focuses on the care of patients with diabetes and other endocrine disorders.

John J. Talley

Job Titles:
  • Member of the Management Team
  • Partner & Vice President - Chemistry
John Talley has led the medicinal chemistry program at Emmyon since 2012. He is one of the world's most accomplished medicinal chemists and an inventor on more than 200 issued U.S. patents. His inventions include the COX-2 specific inhibitors Celebrex®, Bextra®, Dynastat®, Deramaxx® and Trocoxil® and the hydroxyethyl sulfonamide class of inhibitors for the treatment of HIV/AIDS, marketed under the brand names of Agenerase® , Telzir® , and Prezista®. The medicines invented by Dr. Talley have improved the health of millions of patients and generated over $40 billion in sales to date. He received the prestigious PhRMA Discoverers Award in 2002 for the discovery of Celebrex®. For the past five years (2015-2019), Dr. Talley has been named to The Medicine Maker Power List, which recognizes the world's 100 most influential people in drug discovery and development.

Scott M. Ebert

Job Titles:
  • Member of the Management Team
  • Vice President - Biology
Scott Ebert is an accomplished skeletal muscle biologist who joined Emmyon in 2013. He is a scientist in the Division of Endocrinology, Metabolism and Nutrition at Mayo Clinic. His research focuses on mechanisms and treatment of muscle atrophy and diabetes.